Last updated on April 16, 2014 at 21:24 EDT

MediJean Unveils Details on Plans to Lead Medical Marijuana Research and Development in Canada

October 8, 2013

VANCOUVER, Oct. 8, 2013 /CNW/ – MediJean, a bio-pharmaceutical medical
marijuana company, today released details on how the company is leading
research and development around medical marijuana in Canada. The
company says its R&D plans stem from feedback and interviews with
doctors, nurse practitioners and patients across the country who are
calling for a scientific approach to medical marijuana.

Being one of the first companies in Canada to receive a research and
development exemption from Health Canada that permits it to grow
medical marijuana as part of the new Federal Marijuana for Medical
Purposes Regulations (MMPR) program has put MediJean on a clear path to
lead the industry in this field.

MediJean says their commitment to research and development includes
growing the knowledge bank that exists for this important medicine.
Currently they have their scientists performing innovative research on
the over 200 “building block” cannabis strains that hold the most
promise for medical marijuana products. “We believe that through our
systematic isolation of genotypes and marrying of diverse strains into
products that can be tailored for specific disorders, that we can
harness the power and diversity of this remarkable plant, and provide
the best possible choices for our patients,” said Anton Mattadeen,
Chief Strategy Officer at MediJean.

In addition, MediJean will use Gas Chromatograph testing machines that
allow them to not only test their own products but all other marijuana
that is on the market. Testing is essential to ensure that medical
marijuana meets the high standards that patients who need this medicine

“Research and development and quality assurance through testing will be
key factors that will make MediJean stand out,” said Mattadeen. “In
our clean-room laboratories our Ph.D. scientists are working on
cutting-edge research to increase the knowledge base around cannabis.
This will allow us to provide doctors and the medical community with
fact-based research on medical marijuana, as well as provide patients
with the highest quality product available.”

To learn more about how MediJean is moving this industry forward visit http://medijean.com and sign up to receive regular updates.

MediJean is leading the rebirth of medical marijuana through a laser
focus on research, quality and patient experience by implementing best
practices here and around the world. Doctors and Nurse Practitioners
will understand and safely prescribe it within a clinical framework,
patients will have access to clean and affordable medicine, and
university research partners will help the company expand the frontiers
of medical marijuana in the years ahead.


Image with caption: “Dr. Ahad, Ph.D., M.Sc., M.Phil., B.Sc. conducting R&D in one of MediJean’s R&D laboratories. (CNW Group/MediJean)”. Image available at: http://photos.newswire.ca/images/download/20131008_C8171_PHOTO_EN_31828.jpg

Source: PR Newswire